Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
35 Leser
Artikel bewerten:
(0)

DaVita Clinical Research Presents Research Results at the American Nephrology Nurses Association National Symposium

ANAHEIM, Calif., April 14, 2014 /PRNewswire-USNewswire/ -- DaVita Clinical Research (DCR) (NYSE: DVA), a specialty contract research organization with services spanning the full spectrum of drug and device development, today announced that company representatives will present four abstracts at the American Nephrology Nurses Association (ANNA) 45th National Symposium scheduled for April 13-16, 2014 in Anaheim, Calif.

DaVita Clinical Research and Pyxant Labs to Collaborate on Clinical Trials

ANNA is designed to provide an educational and networking environment for nephrology nurses and practice administrators to expand knowledge, enhance clinical skills, and translate evidence into daily practice.

"At DaVita, we're committed to improving the care of patients with renal disease by focusing on translational research," said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president clinical innovation and public policy at DaVita. "Presenting our research initiatives here at ANNA creates an ideal platform to translate those findings into clinical care for kidney patients."

Researchers from DaVita, the dialysis division of DaVita Healthcare Partners Inc., and DCR will present results from a number of innovative clinical improvement programs originating from DaVita and its research partners. DCR seeks to advance the future of medicine, the practice of medicine and to innovate through personalized medicine. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

DaVita will focus on meaningful research initiatives in end-stage renal disease, including:

  • "Choice of Drain Systems and Associated Peritonitis Rates in Automated Peritoneal Dialysis Patients," oral presentation by Michelle Cassin, R.N., C.P.D.N. on Monday, April 14 in Abstract Concurrent Session #162, from 5:35 p.m.-5:55 p.m.
  • "Hemodialysis Session Length Has a Dose Relationship With Hazard Rates of Cause-Specific Hospitalization and Mortality," oral presentation by Irina Goykhman,R.N., B.S.N., M.B.A. on Monday, April 14 in Abstract Concurrent Session #161, from 4:20 p.m.- 4:40 p.m.
  • "A Pilot Quality Improvement Program to Minimize Catheter-Related Bloodstream Infection in an Outpatient Hemodialysis Setting," poster presentation by Nancy Culkin, B.S.N., R.N., C.N.N.
  • "A Standardized Algorithm for Peritonitis Surveillance," poster presentation by Michelle Cassin, R.N., C.P.D.N.

Poster presentations will be held Monday, April 14, 2:45 p.m.-4:15 p.m. and Tuesday, April 15, 9:00 a.m.-10:15 a.m.

DaVita, DaVita Clinical Research, and DCR are trademarks or registered trademarks of DaVita Healthcare Partners Inc.

About DaVita
DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Dec. 31, 2013, DaVita operated or provided administrative services at 2,074 outpatient dialysis centers located in the United States serving approximately 163,000 patients. The company also operated 73 outpatient dialysis centers located in ten countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners Inc. (NYSE: DVA), uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective pragmatic and clinical trials. DCR's scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR's Biorepository, Early Clinical Research unit (Phase I-IIa) and Clinical Development (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes Research, and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.

Logo- http://photos.prnewswire.com/prnh/20140212/DC63568LOGO

Contact Information
Media:
Bianca Violante
Office: (303) 876-661
Mobile: (443) 417-6044
Bianca.Violante@DaVita.com

SOURCE DaVita Clinical Research

© 2014 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.